Skip to main content

Table 1 Demographics and baseline characteristics

From: Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-controlled study

 

Total N = 129

Age (years) Mean (SD)

61.4 (8.9)

Sex–Male, Female, %

67.4, 32.6

Duration of COPD (years), Mean (SD)

6.2 (6.1)

Ex-smoker/smoker, %

46.5/53.5

Pack-years in ex-smokers, mean (SD)

41.1 (16.4)

Pack-years in smokers, mean (SD)

41.0 (16.7)

FEV1 pre-bronchodilator, L, mean (SD)

1.71 (0.58)

FEV1 post-bronchodilator, L, mean (SD)

1.90 (0.51)

FEV1 reversibility, %

10.26

FEV1% predicted (post-bronchodilator), mean (SD)

64.02 (9.38)

FEV1/FVC post-bronchodilator, %

58.98 (10.29)

  1. FEV1, forced expiratory volume in one second; FVC, forced vital capacity.